Upadacitinib, initially investigated as ABT-494, represents a significant advance in targeted therapy for inflammatory ailments. Chemically, it's a targeted Janus kinase (JAK) inhibitor , possessing the molecular https://www.targetmol.com/compound/upadacitinib